IN RESPONSE: Dr. Paul may be reassured to know that we used several strategies to ensure that our study did not include acute upper respiratory tract infections (AURIs) that were bacterial or suspected to be bacterial. First, we limited our analysis to 4 viral AURIs: acute nasopharyngitis, acute sinusitis, acute laryngitis, and acute bronchitis. We did not in- clude those diagnosed with streptococcal pharyngitis; this condition has a specific billing code (034), which enabled us to exclude these patients. As for acute nasopharyngitis, the physician claims submission guide in our region defines the diagnostic code 460 as "acute nasopharyngitis, common cold." Although acute nasopharyngitis in adults has been hypothesized to be a rare separate condition from the common cold, evidence of benefit of antibiotic therapy for either condition is lacking. Current guidelines from the American College of Physicians and the Centers for Disease Control and Prevention state that antibiotic therapy is never indicated for the common cold or acute bronchitis and suggest that it be used only in selected circumstances in acute sinusitis (1) . Second, we further excluded patients at increased risk for bacterial infections or complications (those who were immunosuppressed, had active cancer, or were living in longterm care homes) and any patients who had any investigations, including rapid streptococcal testing, to assess for bacterial infections (Supplement Tables 4 to 6 and 8 of our article).
Finally, we excluded patients who had prolonged episodes or who had an outpatient visit or hospital admission where a bacterial infection was diagnosed (Supplement Table  5 of our article).
Our study thus comprised a cohort of low-risk patients with a high probability of nonbacterial AURIs. That nearly one half of these patients received antibiotic prescriptions and, further, that 70% of these prescriptions were broad-spectrum agents is therefore concerning. Whereas aminopenicillins may sometimes be indicated in a few patients with acute sinusitis, broad-spectrum antibiotics are not recommended for any of the AURIs that we studied (1) .
To test the robustness of our findings, we conducted a sensitivity analysis where 97% of patients had the common cold and 3% had acute laryngitis; more than 30% received antibiotic prescriptions. The high rate of antibiotic prescribing among these low-risk patients with a physician-diagnosed nonbacterial AURI strongly suggests inappropriate prescribing.
Several other studies that observed similarly high rates of antibiotic prescribing for nonbacterial AURIs corroborate our findings (2-4). These results support the need for targeted interventions to help reduce inappropriate antibiotic prescribing. (1) . Among these patients, all but 1 of whom were reported to the U.S. Food and Drug Administration Adverse Event Reporting System, 2 died and 1 required liver transplantation. These important findings highlight viral interactions that can develop in persons who are chronically infected with multiple hepatitis viruses (2) . Bersoff-Matcha and colleagues' article provides details on HBV infection variables for these patients but no information about whether hepatitis D virus (HDV) infection was present, perhaps reflecting inherent limitations of the reporting system. We suggest that this infection, which causes the most aggressive form of human viral hepatitis, might play a role in patients diagnosed with HBV reactivation.
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Hepatitis D virus is an incomplete virus that requires hepatitis B surface antigen (HBsAg) for virion assembly and replication (3). Hepatitis B, C, and D viruses have common routes of infection, and patients with chronic HBV infection often have triple infection (3); in some cohorts of U.S. injection drug users, more than one third of those with detectable HBsAg were co-infected with HDV (4) (Mahale P. Unpublished data.). Hepatitis D virus infection has been associated with fulminant hepatitis and more rapid progression to cirrhosis, hepatic decompensation, and death than is seen in persons who only have HBV infection (3) .
Reports of HBV reactivation after successful treatment of chronic HCV infection show that the latter may suppress HBV replication. Complex interactions have been reported in persons who are triply infected with HBV, HCV and HDV, with some reports suggesting that HCV plays a dominant role overall (2) . If HCV does, indeed, dominate HBV and HDV, treatment for HCV infection with DAAs may enhance replication not only of HBV but also HDV, with a potential for consequent rapid progression of the underlying liver disease.
Recent HCV treatment guidelines recommend that all HCV-infected patients starting DAA therapy be evaluated for HBV co-infection (1); however, patients with positive results on
